Division of Molecular Biology and Human Genetics, South African Medical Research Council Centre for Tuberculosis Research, DSI-NRF Centre of Excellence for Biomedical Tuberculosis Research, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.
Tuberculosis Omics Research Consortium, Family Medicine and Population Health, Institute of Global Health, Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium.
Microbiol Spectr. 2023 Aug 17;11(4):e0111423. doi: 10.1128/spectrum.01114-23. Epub 2023 Jun 26.
Mycobacterium tuberculosis whole-genome sequencing (WGS) is a powerful tool as it can provide data on population diversity, drug resistance, disease transmission, and mixed infections. Successful WGS is still reliant on high concentrations of DNA obtained through M. tuberculosis culture. Microfluidics technology plays a valuable role in single-cell research but has not yet been assessed as a bacterial enrichment strategy for culture-free WGS of M. tuberculosis. In a proof-of-principle study, we evaluated the use of Capture-XT, a microfluidic lab-on-chip cleanup and pathogen concentration platform to enrich M. tuberculosis bacilli from clinical sputum specimens for downstream DNA extraction and WGS. Three of the four (75%) samples processed by the microfluidics application passed the library preparation quality control, compared to only one of the four (25%) samples not enriched by the microfluidics M. tuberculosis capture application. WGS data were of sufficient quality, with mapping depth of ≥25× and 9 to 27% of reads mapping to the reference genome. These results suggest that microfluidics-based M. tuberculosis cell capture might be a promising method for M. tuberculosis enrichment in clinical sputum samples, which could facilitate culture-free M. tuberculosis WGS. Diagnosis of tuberculosis is effective using molecular methods; however, a comprehensive characterization of the resistance profile of Mycobacterium tuberculosis often requires culturing and phenotypic drug susceptibility testing or culturing followed by whole-genome sequencing (WGS). The phenotypic route can take anywhere from 1 to >3 months to result, by which point the patient may have acquired additional drug resistance. The WGS route is a very attractive option; however, culturing is the rate-limiting step. In this original article, we provide proof-of-principle evidence that microfluidics-based cell capture can be used on high-bacillary-load clinical samples for culture-free WGS.
结核分枝杆菌全基因组测序(WGS)是一种强大的工具,因为它可以提供关于种群多样性、耐药性、疾病传播和混合感染的数据。成功的 WGS 仍然依赖于通过结核分枝杆菌培养获得的高浓度 DNA。微流控技术在单细胞研究中发挥了宝贵的作用,但尚未被评估为结核分枝杆菌无培养 WGS 的细菌富集策略。在一项原理验证研究中,我们评估了 Capture-XT 的使用,这是一种微流控片上实验室清洁和病原体浓缩平台,用于从临床痰液标本中富集结核分枝杆菌杆菌,用于下游 DNA 提取和 WGS。通过微流控应用程序处理的四个样本中的三个(75%)通过了文库制备质量控制,而未通过微流控结核分枝杆菌捕获应用程序富集的四个样本中的一个(25%)通过。WGS 数据质量足够高,映射深度≥25×,9%至 27%的读取映射到参考基因组。这些结果表明,基于微流控的结核分枝杆菌细胞捕获可能是一种有前途的方法,用于富集临床痰液样本中的结核分枝杆菌,这可以促进无培养结核分枝杆菌 WGS。使用分子方法诊断结核病是有效的;然而,结核分枝杆菌耐药谱的全面特征通常需要培养和表型药敏试验或培养后进行全基因组测序(WGS)。表型途径可能需要 1 到>3 个月的时间才能得出结果,在此期间,患者可能已经获得了额外的耐药性。WGS 途径是一个非常有吸引力的选择;然而,培养是限速步骤。在这篇原始文章中,我们提供了初步证据,证明基于微流控的细胞捕获可以用于高细菌负荷的临床样本,进行无培养 WGS。